Can Oral GLP-1 Therapies Overtake Injectables
Disclosures: Alyssa Goldberg: Nothing to Disclose, William Hollenbach: Nothing to Disclose, Cara Mack: Nothing to Disclose, Beth Tamburini: Nothing to Disclose 2499 REQUIRED DOSE AND EFFECTS OF NTBC TREATMENT FOR HEREDITARY TYROSINEMIA TYPE 1: CONFIRMATIONS AND SURPRISES FROM A NOVEL, REPRESENTATIVE HUMAN MODEL Farzaneh Tamnanloo 1 Quang Toan Pham 1 Marie-Agns MCallum 1 Denis Cyr 2 Paula Waters 2 Emilie Beaulieu 1 Yannick Doyon 3 Ugur Halac 4 Claudia Raggi 1 Massimiliano Paganelli 4 , 1 Liver Tissue Engineering and Cell Therapy Laboratory, CHU Sainte-Justine, Montral, Canada, 2 Department of Biochemistry, Universit de Sherbrooke, Sherbrooke, Canada, 3 Department of Molecular Medicine, Universit Laval, Quebec, Canada, 4 Department of Pediatrics, Universit de Montral, Montral, Canada Background: Hereditary Tyrosinemia Type 1 (HT1) is a severe genetic liver disorder caused by a deficiency in fumarylacetoacetate hydrolase (FAH), a key enzyme of tyrosine metabolic pathway
doi: 10.1016/j.bbr.2018.08.006 Summary Keywords Alzheimers disease, GLP-1R agonists, cognitive function, amyloid beta, tau phosphorylation Citation Du H, Meng X, Yao Y and Xu J (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimers disease
Slowed Stomach Emptying: GLP-1 slows the rate at which your stomach empties, keeping you fuller for longer and leading to a gradual rise in blood sugar after eating
Ten trials involved individuals with T2D [25,27,30-37], while three focused on obese or overweight subjects without diabetes [26,28,29]
